BioPharma Dive January 20, 2026
Kristin Jensen

The acquisition hands GSK most rights to a treatment Rapt licensed last year from a China-based drugmaker and could emerge as a preventive therapy for a variety of food-related allergens.

Dive Brief:

  • GSK on Tuesday said it’s agreed to buy Rapt Therapeutics for $2.2 billion, gaining access to a drug that promises to help a wider population of patients avoid allergic reactions to food.
  • The medicine, ozureprubart, targets the immunoglobulin E, or IgE antibodies that are produced when a patient’s immune system overreacts after encountering allergens. Once released, the IgE antibodies help trigger allergic reactions that can sometimes be deadly for patients.
  • Ozureprubart is currently in Phase 2b testing, and Rapt believes it has the potential to be...

Today's Sponsors

Venturous
ZeOmega

Today's Sponsor

Venturous

Continue Reading

 
Topics: Biotechnology, Mergers & Acquisitions / JV, Pharma, Pharma / Biotech, Trends
Related Articles:
Q&A: New PQA Resource Highlights 40 Projects Targeting Social Determinants of Health
Data Visualization is Broken in Biotech: Q&A with Sunitha Venkat
Biotech investor Cormorant secures $150M for another SPAC deal
The Future of Pharmacovigilance Technology: How AI and Automation Are Redefining Drug Safety
Introducing the Sunday Times Tech 100: Life sciences part 1

Share Article